Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial.

Chen, Jia-Hao; Liu, Xu; Chen, Kang; Hu, Xiao-Yin; Xiang, Bang-De; Yuan, Wei-Ping

Chen, Jia-Hao; Liu, Xu; Chen, Kang; Hu, Xiao-Yin; Xiang, Bang-De; Yuan, Wei-Ping.

Afiliação

Chen JH; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Liu X; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Chen K; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Hu XY; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Xiang BD; Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Yuan WP; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning 530021, China.

Transl Cancer Res ; 9(1): 400-401, 2020 Jan.

Article em En | MEDLINE | ID: mdl-35117195

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Cancer Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google